

## SCHEDULES

### SCHEDULE 2

Amendment of the Human Medicines (Amendment etc.) (EU Exit) Regulations 2019

#### PART 4

Amendment of Part 5 (amendment of Part 5 (marketing authorisations))

**58.** In regulation 80(2) (amendment of regulation 71 (withdrawal of medicinal product from the market)) for sub-paragraph (b) substitute—

“(b) for sub-paragraph (b) substitute—

“(b) under—

- (i) regulation 69 the licensing authority suspends the use, sale, supply or offer for sale or supply within Great Britain of a product to which a UKMA(GB) relates; or
- (ii) regulation 69 or Article 20(4) of Regulation (EC) No 726/2004 the licensing authority suspends the use, sale, supply or offer for sale or supply within Northern Ireland of a product to which a UKMA(NI) or UKMA(UK) relates.””.

#### Commencement Information

**II** Sch. 2 para. 58 in force at 31.12.2020 immediately before IP completion day, see [reg. 1](#)

**Changes to legislation:**

There are currently no known outstanding effects for the The Human Medicines (Amendment etc.) (EU Exit) Regulations 2020, Paragraph 58.